Literature DB >> 6469753

Pharmacology and toxicology of sensitizers: mechanism studies.

A M Rauth.   

Abstract

Nitroimidazoles are being studied extensively as hypoxic cell radiosensitizers. Besides their ability to selectively sensitize hypoxic cells to radiation, which depends on the parent compound, nitroimidazoles have a variety of other effects in vitro, in vivo and clinically which appear to require reductive metabolism. These other effects include direct cytotoxicity to hypoxic cells, mutagenicity and antimicrobial effects. As a first step to suggesting possible mechanisms for these other biological effects, a summary has been made of the known oxidative and reductive products of the two most widely studied radiosensitizers, metronidazole and misonidazole. Focussing on reductive products, it is clear that a great variety exists which are or may be reactive with biological molecules. Knowledge about the reduction chemistry of nitroimidazoles is new and far from complete. As a second step to suggesting possible mechanisms for these biological effects, it is important to view the problem in terms of the in vivo situation where distribution and sites of metabolism of the drug and its reduction products will be important factors. Variables such as levels of tissue oxygenation and nitroreductase activity will be important to assess. Combining basic information about the reduction chemistry of nitroimidazoles with knowledge about the pharmacology of drugs and their reduced products should allow a better assessment of mechanism of action as well as a better implementation of these drugs clinically.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469753     DOI: 10.1016/0360-3016(84)90335-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  5-Dimethyl-amino-N,N-dimethyl-2-nitro-benzamide.

Authors:  Hoong-Kun Fun; Samuel Robinson Jebas; B Chandrakantha; Vijaya Padmar; Arun M Isloor
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-05-20

Review 2.  Cellular approaches to bioreductive drug mechanisms.

Authors:  A M Rauth; R S Marshall; B L Kuehl
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

3.  Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice.

Authors:  M I Walton; N M Bleehen; P Workman
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

4.  NAD(P)H nitroblue tetrazolium reductase levels in apparently normoxic tissues: a histochemical study correlating enzyme activity with binding of radiolabelled misonidazole.

Authors:  L M Cobb; T Hacker; J Nolan
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

5.  Use of a high frequency ultrasound microscope to image the action of 2-nitroimidazoles in multicellular spheroids.

Authors:  L R Bérubé; K Harasiewicz; F S Foster; E Dobrowsky; M D Sherar; A M Rauth
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

6.  Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.

Authors:  L M Cobb; J Nolan; S A Butler
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

7.  Microscopic distribution of misonidazole in mouse tissues.

Authors:  L M Cobb; J Nolan; P O'Neill
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

8.  Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells.

Authors:  M B Parliament; L I Wiebe; A J Franko
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

9.  Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study.

Authors:  M B Parliament; J D Chapman; R C Urtasun; A J McEwan; L Golberg; J R Mercer; R H Mannan; L I Wiebe
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

10.  The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice.

Authors:  M I Walton; N M Bleehen; P Workman
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.